Canada-based bioLytical Laboratories has introduced INSTI HIV Self Test in pharmacies across Belgium.

The simple test requires only a single drop of blood to provide instant and more than 99% accurate results. This is contrary to other home tests, which require 15 to 20 minutes, or laboratory tests that need several days or weeks to generate results.

The test is an over-the-counter (OTC) version of the existing INSTI point-of-care check in Europe.

bioLytical president Robert Mackie said: "When developing an HIV home test, we wanted to provide an easy and affordable, consumer-friendly solution that would empower individuals to take control of their health in a discrete way, and within the comfort of their own home.

"By launching in Belgium, we are able to make HIV screening more accessible.

"INSTI HIV Self Test can detect HIV up to two weeks sooner than all other HIV home tests currently on the market."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"INSTI HIV Self Test can detect HIV up to two weeks sooner than all other HIV home tests currently on the market."

bioLytical's in-country sales team is set to launch the test in approximately 4,900 pharmacies in the country.

Using its INSTI technology platform, the company develops and commercialises point-of-care in-vitro medical diagnostics.

The firm sells its US Food and Drug Administration, Health Canada approved and CE-marked INSTI HIV test in multiple markets, while its INSTI HIV/Syphilis Multiplex test is sold in Europe.

bioLytical's pipeline includes diagnostic tests for diseases such as Zika, Dengue, Chikungunya, Hepatitis C, and Ebola.